1,101 posts by 291 firms and lawyers
Cannabis law explained by the lawyers who practise it: analysis and commentary from law firms around the world, with the Cannabis Law Journal.
Since the April 2026 filing season, the landscape surrounding Section 280E of the Internal Revenue Code has continued to evolve in significant ways. , d/b/a Ultra Health v.
On April 23, 2026, the Department of Justice and the Drug Enforcement Administration issued an order moving medical marijuana subject to a state license from Schedule I to Schedule III of the Controlled Substances Act.
On April 23, 2026, the DOJ and DEA issued a final order rescheduling certain marijuana products from Schedule I to Schedule III of the Controlled Substances Act. The order is subject to litigation, but it remains in effect for…
This is the second installment in a series on what 1,446 pages of FOIA-ed IRS cannabis training materials reveal. ” This one is about something the IRS places too much faith in: your cannabis business’s METRC data.
The Drug Enforcement Administration is scheduled to hold a historic hearing beginning Monday, June 29, 2026, which could extend Schedule III cannabis rescheduling to adult-use marijuana and reshape the federal regulatory…
Article by: Ivy Perez-Bader, Raza Lawrence, Jana Weltzin, Greg Cowan, and Tom Zuber
The week of April 18 through April 23, 2026 produced two distinct and legally consequential federal actions on controlled substances. On April 18, President Trump signed Executive Order 14401, directing the federal government to…
Today, April 23, 2026, the United States Acting Attorney General, Todd Blanche, (the “AG”) and the U.S. Department of Justice (“DOJ”) announced the issuance of a final order that “immediately places” some cannabis into Schedule…
The rescheduling of certain cannabis products to Schedule III represents a meaningful shift in federal cannabis policy and offers long-awaited tax relief for portions of the industry.
On April 23, 2026, as we discussed in our prior client alert, the Department of Justice issued a Final Order immediately placing cannabis “subject to a state medical marijuana license” in Schedule III of the Controlled Substances…
This is the second of 13 posts describing the impacts of marijuana’s rescheduling. An homage to Phish’s historic run at Madison Square Garden in the Summer of 2017, Budding Trends Baker’s Dozen will address how rescheduling…
Medical cannabis products moved to Schedule III and to become fully legal with DEA Registration; Possibility for Adult-Use Rescheduling in Upcoming Hearing
On April 22, 2026, a final order issued by the acting U.S. attorney general and the Drug Enforcement Administration took effect, fundamentally altering the federal regulatory landscape for marijuana. The order moves FDA-approved…
Schedule I → Schedule III: A Landmark Policy Shift with Important Limits
In the last year or two, we have seen a growing number of marijuana businesses take the position that IRC 280E no longer applies to them. Some of these businesses have taken that position in consultation with lawyers and CPAs.
On December 18, 2025, President Donald Trump signed an Executive Order titled Increasing Medical Marijuana and Cannabidiol Research, marking the most consequential federal cannabis policy action in decades.
President Trump’s new Executive Order (EO) is historic, not only because it directs the rescheduling of cannabis from Schedule I to Schedule III, but because it also directs Congress to revise the “hemp ban” language in the 2026…
On December 18, President Trump issued an executive order (EO) directing the Attorney General to complete rulemaking to reschedule “marijuana” from Schedule I to Schedule III under the Controlled Substances Act (CSA) and to…
” Currently, marijuana is a Schedule I drug under the Controlled Substances Act (CSA). The Drug Enforcement Agency began the rescheduling process under President Biden, but that process was uncompleted when President Biden left…
C. ” The announcement was made during an Oval Office meeting with Health and Human Services Secretary Kennedy, senior administration officials, doctors and veterans who advocate for increased access to medical cannabis.